Physician profile
Dean J Railey
NPI 1801869987
$5,831.01
in general payments reported to CMS, 2019-2025
26 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $379 · 2021: $421 · 2022: $405 · 2023: $857 · 2024: $1,229 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,844.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,593.31 | 2019-2025 | |
| Janssen Biotech, INC. | $1,067.17 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $529.68 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.28 | 2019-2025 | Xifaxan, Plenvu |
| Boston Scientific Corporation | $371.27 | 2019-2024 | Autotome Rx 49, Exalt Model D, Compliance Endokit |
| Madrigal Pharmaceuticals | $248.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $227.23 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $176.11 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $171.21 | 2024-2025 | Omvoh |
| Genzyme Corporation | $132.10 | 2025 | |
| Aimmune Therapeutics, INC. | $111.51 | 2024-2025 | Zenpep |
| Celgene Corporation | $104.72 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $101.59 | 2024-2025 | Voquezna |
| Pfizer INC. | $89.68 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $73.42 | 2019-2024 | Dificid, Zinplava |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $69.03 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $56.96 | 2021-2023 | |
| Allergan, INC. | $46.49 | 2019 | |
| Ironwood Pharmaceuticals, INC | $45.77 | 2023 | Linzess |
| Novo Nordisk INC | $45.19 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $39.06 | 2023 | Idacio |
| Evoke Pharma, INC. | $37.12 | 2023 | Gimoti |
| Alnylam Pharmaceuticals INC. | $29.67 | 2025 | Givlaari |
| Shire North American Group INC | $19.16 | 2019 | |
| Redhill Biopharma INC. | $15.95 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $9.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Railey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.